Bayer profits jump in second quarter | Business | Economy and finance news from a German perspective | DW | 29.07.2015

Visit the new DW website

Take a look at the beta version of We're not done yet! Your opinion can help us make it better.

  1. Inhalt
  2. Navigation
  3. Weitere Inhalte
  4. Metanavigation
  5. Suche
  6. Choose from 30 Languages


Bayer profits jump in second quarter

German pharmaceutical giant Bayer has posted a surprising jump in net profit for the second quarter, lifted by strong currency effects and gains in its health care, specialty plastics and agricultural chemicals sectors.

Bayer on Wednesday logged a 21 percent on-the-year rise in net profit in the second quarter of 2015. The gains brought the Leverkusen, Germany-based company's total net profits to 1.15 billion euros ($1.27 billion) for the three-month period ending June 30, compared to last year's 953 million euros.

Bayer cited earnings growth in all three of its business areas as a reason for the strong results. Group sales rose to 12.09 billion euros, an 18.2 percent increase over the same period one year prior.

Sales at its health care division, which includes the company's pharmaceuticals and over-the-counter businesses, were up 28 percent to 5.9 billion euros. That division was also bolstered by a recent acquisition of Bayer's, which saw it absorb US-based Merck's over-the-counter products.

Sales of two of Bayer's newest drugs, a blood thinner and an eye medicine, rose by 42.6 percent and 49.1 percent, respectively.

Bayer also runs a specialty plastics operation known as MaterialScience, which the company has been preparing to spin off for the sake of streamlining. That could be done through an initial public offering, which Bayer CEO Marijn Dekkers has said he would prefer in order to raise money to pay down the company's 20 billion-euro debt.

CropScience, Bayer's agricultural chemicals business, was also boosted by positive currency effects in the second quarter. That division saw its earnings before interest, taxes, depreciation and amortization (Ebitda) jump by 19.2 percent.

The fluctuations in exchange rates have helped Bayer on the whole, but the company still adjusted down its full-year sales outlook to 47 billion euros from 48-49 billion euros.

cjc/bea (dpa, Reuters)